2,374 material Form 8-K filings that 2,009 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Sezzle furnished an investor presentation dated November 9, 2026, which it may use with investors starting that day. The presentation raises fiscal 2026 adjusted net income guidance to $190.0 million from $185.0 million and adjusted earnings per diluted share guidance to $5.45 to $5.50 from $5.25, and reports 955,000 active subscribers as of September 30, 2026. Adjusted figures are non-GAAP, and the company says prior guidance was not recast for tax effects, so the comparisons are not direct.
FY2026 adjusted net income guidance of $190.0 million, up from $185.0 million in the August update
FY2026 adjusted net income per diluted share guidance of $5.45 to $5.50, up from $5.25
955,000 active subscribers as of September 30, 2026, up 68.1% year over year
Investor presentation (Exhibit 99.1) dated November 9, 2026 may be used beginning that date
Summit Midstream reported third quarter 2026 net income of $15.9 million, compared with $5.0 million a year earlier, and raised its full-year 2026 Adjusted EBITDA guidance to $250 million to $260 million from $235 million to $255 million. Common stock dividends remain suspended, and the company's total net leverage ratio was approximately 3.9x as of September 30, 2026.
Q3 2026 net income $15.9 million vs. $5.0 million in Q3 2025; diluted EPS $0.58 vs. a loss of $0.13
Total revenues $183.0 million vs. $146.9 million a year earlier; Adjusted EBITDA $70.7 million vs. $65.5 million
2026 Adjusted EBITDA guidance raised to $250 million to $260 million from $235 million to $255 million
Common stock dividends remain suspended; Series A Preferred dividend payable to holders of record on December 1, 2026
Tidewater reported third-quarter 2026 revenue of $360.4 million, up from $341.1 million a year earlier, and net income attributable to the company of $17.5 million, or $0.35 per diluted share, compared with a loss of $0.8 million a year earlier. The company also initiated 2027 revenue guidance of $1.70 to $1.75 billion and updated its 2026 revenue guidance to $1.43 to $1.44 billion, while closing a $500 million all-cash acquisition of Wilson Sons Ultratug Offshore.
Q3 2026 revenue of $360.4 million, up 5.3% from the second quarter of 2026
Q3 2026 net income of $17.5 million ($0.35 per diluted share), versus a $0.8 million loss a year earlier
Nine-month 2026 net income of $45.3 million, down from $114.8 million in the first nine months of 2025
2027 revenue guidance of $1.70 to $1.75 billion; 2026 revenue guidance updated to $1.43 to $1.44 billion
Elmet Group reported third-quarter 2026 results for the period ended October 2, 2026, with revenue up 55.6% to $79.6 million and net income of $8.3 million, or $0.24 per diluted share, compared with $1.6 million, or $0.08, a year earlier. Gross margin rose to 31.3% and open order backlog reached a company record $347.4 million, though nine-month net income fell to $3.5 million from $4.0 million and the release gives no new guidance.
Q3 revenue was $79.6 million versus $51.1 million a year earlier; gross profit margin was 31.3% versus 21.7%.
Adjusted EBITDA was $17.0 million, or 21.3% of revenue, versus $7.4 million, or 14.5%, in Q3 2025.
Q3 net income was $8.3 million, or $0.24 per diluted share, versus $0.08 per diluted share a year earlier.
Nine-month net income was $3.5 million, or $0.10 per diluted share, versus $4.0 million, or $0.20, for the nine months ended September 30, 2025.
AST SpaceMobile reported third quarter 2026 revenue of $42.3 million, up from $14.7 million a year earlier, and a net loss attributable to common stockholders of $132.4 million, or $0.44 per share, compared with $122.9 million, or $0.45 per share, in the third quarter of 2025. The company said it remains on target for its revenue guidance of $150.0 million to $200.0 million and cited about $1.0 billion in non-dilutive Japanese government funding for satellite manufacturing and launch.
Q3 2026 total revenue was $42.3 million versus $14.7 million in Q3 2025; nine-month revenue was $88.6 million versus $16.6 million
Net loss attributable to common stockholders was $132.4 million, or $0.44 per share, versus $122.9 million, or $0.45 per share, a year earlier
Company remains on target for 2026 revenue guidance of $150.0 million to $200.0 million
Cash, cash equivalents and restricted cash were approximately $3.2 billion as of September 30, 2026
QXO Chairman and CEO Brad Jacobs said on a November 9, 2026 conference call that September sales were much stronger than expected and that the company pre-released third-quarter adjusted EBITDA of $557 million on revenue of $4.9 billion, an 11.4% margin. He also said his family office will lead a $1 billion cash investment in NYSE American-listed CKX Lands, under which he would own a majority stake and become its chairman and CEO while remaining QXO's chairman and CEO.
Preliminary Q3 adjusted EBITDA of $557 million on revenue of $4.9 billion, an adjusted EBITDA margin of 11.4%
Companywide pricing improved 2.2% year-over-year in Q3; daily sales rose 5.4% year-over-year across the company in October
$1 billion CKX investment: $900 million from Jacobs Private Equity and $100 million from co-investors led by Heritage Partners, with CKX stockholder approval still required
Long-term target of $4 billion adjusted EBITDA by 2030 before additional acquisitions, versus roughly $1.75 billion in current consensus estimates
Mesa Laboratories reported fiscal second-quarter revenue of $62.3 million, up 2.6%, and net income of $4.3 million, up 75.3%, or $0.75 per diluted share versus $0.45 a year earlier. The company also issued its first fiscal 2027 guidance, calling for revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, and authorized a share repurchase of up to $40 million.
Q2 revenue $62.3 million, up 2.6%; adjusted EBITDA $17.3 million, up 21.1%, or 27.8% of revenue
Fiscal 2027 guidance (year ending March 31, 2027): revenue $250 million to $255 million; adjusted EBITDA $66 million to $68 million
Board terminated its 2005 buyback program on November 4, 2026 and authorized up to $40 million in repurchases through December 31, 2028
Savings Plan announced October 13, 2026 expects total pre-tax restructuring charges of $2.6 million to $3.4 million, mainly in the second half of fiscal 2027
Babcock & Wilcox reported third quarter 2026 revenue of $290.8 million, up from $139.2 million a year earlier, and net income of $93.9 million, up from $35.1 million. Net income was lifted by an $85.1 million change in the fair value of customer warrants, and adjusted net income was $4.8 million. The company reiterated its 2026 Adjusted EBITDA target of $80.0 million to $105.0 million and issued a 2027 Adjusted EBITDA target of $125 million to $140 million.
Q3 2026 revenue of $290.8 million vs. $139.2 million in Q3 2025; Adjusted EBITDA of $17.7 million vs. $9.4 million
Net income of $93.9 million includes an $85.1 million change in fair value of customer warrants; adjusted net income was $4.8 million
Basic EPS of $0.61 vs. $0.30 in Q3 2025; Q3 bookings of $228 million and backlog of $2.5 billion
2026 Adjusted EBITDA target of $80.0 million to $105.0 million reiterated; 2027 target of $125 million to $140 million issued
P3 Health Partners reported third quarter 2026 revenue of $396 million, up 15% from a year earlier, and net income of $30.8 million versus a net loss of $69.5 million in the prior-year quarter. The company raised the low end of its full-year 2026 Adjusted EBITDA guidance to $90 million, moving the midpoint to $100 million, though the quarter also benefited from payer settlements and prior-year development.
Q3 2026 total revenue was $396 million, up 15% from $345 million a year earlier.
Q3 2026 Adjusted EBITDA was $20.9 million, compared with a loss of $45.9 million in Q3 2025.
Full-year 2026 Adjusted EBITDA guidance is now $90 million to $110 million, up from a lower low end.
Q3 medical margin of $43.9 million included favorable payer settlements; excluding these items it was $35.0 million.
Coherus Oncology reported third quarter 2026 net revenue from continuing operations of $14.3 million, up from $11.6 million a year earlier, and a narrower net loss from continuing operations of $38.9 million, or $(0.25) per share, versus $44.5 million, or $(0.38) per share. The company also announced a strategic prioritization plan that focuses tagmokitug development on esophageal cancer and reduces headcount by about 30%, with the CFO saying these benefits will be realized over the next two quarters.
Q3 2026 net revenue from continuing operations was $14.3 million, versus $11.6 million in Q3 2025; LOQTORZI revenue was $14.0 million, up 25% from $11.2 million.
Q3 2026 GAAP net loss from continuing operations was $38.9 million, or $(0.25) per share, versus $44.5 million, or $(0.38) per share, in Q3 2025.
Right-sizing reduces headcount by about 30% and is expected to lower core cash burn by $6 million to $7 million per quarter.
Cash, cash equivalents and marketable securities were $83.6 million at September 30, 2026, versus $172.1 million at December 31, 2025.
Lincoln Educational Services reported third-quarter 2026 revenue of $159.2 million, up 12.6% from $141.4 million, with net income of $4.7 million, up from $3.8 million. The company raised its full-year 2026 revenue guidance to $600.0 million to $605.0 million while reiterating its adjusted EBITDA guidance of $76.0 million to $80.0 million.
Q3 2026 revenue of $159.2 million, up from $141.4 million; net income of $4.7 million, up from $3.8 million
Diluted EPS of $0.15 versus $0.12; adjusted EBITDA of $17.4 million, up 30.8%
2026 revenue guidance raised to $600.0 million to $605.0 million; student start growth guidance narrowed to 10% to 12%
Board raised the share repurchase authorization by $30 million to $70 million total, with more than $37 million remaining
AMCON Distributing reported results for the fiscal year ended September 30, 2026, with diluted earnings per share of $2.52 compared with $0.62 in the prior year. Sales rose to $3.12 billion from $2.82 billion, and the retail health food segment posted an operating loss while the wholesale segment reported operating income.
Net income available to common shareholders was $2.4 million, compared with $0.6 million in fiscal 2025.
Sales were $3.12 billion, compared with $2.82 billion in fiscal 2025.
Wholesale distribution segment operating income was $25.5 million; retail health food segment operating loss was $0.6 million.
Shareholders' equity was $117.0 million at September 30, 2026.
Life360 reported third-quarter 2026 total revenue of $174.1 million, up 40% from a year earlier, with net income of $22.5 million, up 130%, including a $17.5 million investment fair value gain. The company narrowed its full-year 2026 guidance for consolidated revenue to $665 million to $681 million and for Adjusted EBITDA to $132 million to $138 million, and reported $44.4 million in share repurchases to date.
Q3 2026 total revenue of $174.1 million, up 40% YoY; advertising revenue of $25.4 million, up 250% YoY
Net income of $22.5 million, up 130% YoY, including a $17.5 million net gain on fair value of investments
Adjusted EBITDA of $34.6 million, up 41% from $24.5 million in Q3 2025
FY26 consolidated revenue guidance of $665 million to $681 million, versus the prior $650 million to $685 million; Adjusted EBITDA guidance of $132 million to $138 million, narrowed from $130 million to $140 million
Greystone Housing Impact Investors LP reported third-quarter 2026 net income of $3.2 million, or $0.09 per BUC, compared with $851,000 in the same quarter of 2025, and total revenues of $21.95 million, up from $21.11 million. Cash Available for Distribution was $3.8 million, or $0.17 per BUC, versus $0.18 a year earlier, and the quarterly distribution was $0.14 per BUC, down from $0.30 in the prior-year quarter. The partnership is reducing its market-rate multifamily joint venture equity investments and redeploying capital into tax-exempt mortgage revenue bonds, and it said the pace of sales will affect near-term results.
Q3 2026 net income of $3.2 million, or $0.09 per BUC, versus $851,000, or $(0.01) per BUC, in Q3 2025
Total revenues of $21.95 million for Q3 2026, versus $21.11 million a year earlier
Quarterly distribution of $0.14 per BUC, paid October 30, 2026, versus $0.30 declared in Q3 2025
Five MRBs tied to a single borrower were behind on debt service as of September 30, 2026; payments were received on four of the five as of the filing date
Qualys reported third-quarter 2026 revenue of $188.0 million, up 11% from $169.9 million a year earlier, and GAAP diluted earnings of $1.62 per share versus $1.39. The company raised its full-year 2026 revenue guidance to $736.9 million-$738.9 million from $732.0 million-$738.0 million and its GAAP EPS guidance to $6.08-$6.15 from $5.76-$5.90, which points to a higher outlook for shareholders.
Q3 revenue $188.0 million, up 11% from $169.9 million; GAAP net income $57.2 million
GAAP diluted EPS $1.62 vs. $1.39; non-GAAP diluted EPS $2.12 vs. $1.86
Full-year 2026 revenue guidance raised to $736.9 million-$738.9 million; GAAP EPS guidance raised to $6.08-$6.15
Q4 2026 revenue guidance set at $191.0 million-$193.0 million, 9% to 10% growth
Larimar Therapeutics said it completed its rolling Biologics License Application with the FDA, seeking accelerated approval of nomlabofusp for Friedreich's ataxia. The company also disclosed a preliminary, unaudited $128.7 million in cash, cash equivalents and marketable securities as of September 30, 2026, with its quarter-end close not yet complete, so shareholders should note that figure could change.
Rolling BLA submission to the FDA completed; the company seeks accelerated approval based on skin frataxin as a potential novel surrogate endpoint.
Preliminary cash, cash equivalents and marketable securities of approximately $128.7 million as of September 30, 2026, subject to change after financial statement closing procedures.
The updated corporate deck projects cash runway into late Q2 2027 and lists BLA acceptance for early 2027 and U.S. approval for mid-2027 as estimated timing.
ZipRecruiter reported third quarter 2026 revenue of $124.4 million, up 8% year-over-year and above its $118 million to $124 million guidance range, and net income of $5.1 million compared with a net loss of $9.8 million a year earlier. The company raised its full-year 2026 revenue outlook to $468 million to $472 million, up 4% to 5%, from the flat outlook it gave at the start of the year.
Q3 2026 revenue was $124.4 million, up 8% year-over-year and 5% quarter-over-quarter; Adjusted EBITDA was $20.8 million, above the $13 million to $19 million guidance.
Q3 2026 net income was $5.1 million, a 4% net income margin, versus a net loss of $9.8 million in Q3 2025.
Full-year 2026 revenue outlook is $468 million to $472 million; full-year Adjusted EBITDA outlook is $61 million to $65 million.
Q4 2026 guidance calls for revenue of $118 million to $122 million and Adjusted EBITDA of $16 million to $20 million.
PubMatic reported third-quarter 2026 revenue of $79.6 million, up 17% from a year earlier, and GAAP net income of $5.5 million, or $0.11 per diluted share, compared with a net loss of $6.5 million in the prior-year quarter. Its Board also authorized an additional $150 million for share repurchases and extended the program through December 31, 2028, bringing the total available to approximately $198 million.
Q3 2026 revenue was $79.6 million, up 17% year over year; adjusted EBITDA was $26.0 million, versus $11.2 million in Q3 2025.
GAAP net income was $5.5 million ($0.11 per diluted share), compared with a net loss of $6.5 million ($0.14 per share) in Q3 2025.
Q4 2026 revenue guidance is $91 million to $93 million, and full-year 2026 revenue guidance is $312 million to $314 million.
On November 9, 2026, the Board authorized $150 million of additional repurchases, with the program running through December 31, 2028.
Zymeworks reported third quarter 2026 net income of $173.7 million, compared with a net loss of $19.6 million a year earlier, driven mainly by a $250 million milestone from Jazz Pharmaceuticals after the U.S. approval of Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma. The company raised its 2026 total revenue guidance to $337 million to $351 million from $278 million to $292 million. Higher selling, general and administrative costs tied to the Theravance Biopharma acquisition partly offset the gain.
Q3 2026 total revenue was $256.5 million, compared with $27.6 million in Q3 2025.
Q3 2026 diluted earnings per share were $2.28, compared with a loss of $0.26 per share in Q3 2025.
2026 adjusted EBITDA guidance was raised to $176 million to $190 million from $114 million to $128 million.
SG&A expenses rose to $42.7 million from $14.1 million, mainly due to Theravance Biopharma acquisition costs, which closed September 23, 2026.
Onto Innovation reported fiscal third-quarter 2026 revenue of $409.7 million, up 87.8% from a year earlier, with GAAP net income of $46.8 million, or $0.95 diluted EPS, versus $0.57 a year earlier. The company also guided fourth-quarter 2026 revenue to $430 million to $450 million and non-GAAP diluted EPS to $2.59 to $2.79, while a $40.8 million unrealized loss on its Rigaku investment weighed on GAAP results.
Q3 revenue of $409.7 million vs. $218.2 million in Q3 2025; non-GAAP diluted EPS of $2.44 vs. $0.92
GAAP net income of $46.8 million includes a $40.8 million unrealized loss on the Rigaku investment
Q4 2026 guidance: revenue of $430 million to $450 million; GAAP diluted EPS of $1.95 to $2.07
Cash, equivalents and marketable securities of $1.25 billion at September 30, 2026; backlog above $1.3 billion
Kaltura reported third-quarter 2026 total revenue of $47.3 million, up 8% from a year earlier, and a net loss of $1.5 million, or $0.01 per diluted share, narrowed from $2.6 million in the prior-year quarter. The company raised its full-year 2026 guidance for subscription revenue, total revenue and adjusted EBITDA for the third time this year, which matters to shareholders because it signals stronger expected results, although Media & Telecom revenue declined 10%.
Total revenue was $47.3 million, up 8% from $43.9 million; subscription revenue was $45.9 million, up 9%.
Full-year 2026 total revenue guidance is now $185.0 million to $185.7 million, and adjusted EBITDA guidance is $19.5 million to $20.5 million.
Net loss was $1.5 million, or $0.01 per diluted share, compared with $2.6 million, or $0.02, in Q3 2025.
Media & Telecom revenue fell 10% year over year, while cash flow from operations was $7.6 million.
Sanmina reported unaudited fourth-quarter fiscal 2026 results for the quarter ended October 3, 2026, with revenue of $3.86 billion, GAAP diluted EPS of $2.14 versus $0.88 a year earlier, and gave fiscal 2027 revenue guidance of $17.5 billion to $19.5 billion. The company also disclosed Amendment No. 5 to its credit agreement, which adds $70 million of term A loans and extends key debt maturities to October 28, 2031.
Q4 revenue $3.86 billion vs $2.10 billion a year earlier; GAAP diluted EPS $2.14 vs $0.88; non-GAAP diluted EPS $4.43 vs $1.67
Q1 fiscal 2027 outlook: revenue $3.8 billion to $4.1 billion; non-GAAP diluted EPS $3.50 to $3.85
Fiscal 2027 outlook: revenue $17.5 billion to $19.5 billion; non-GAAP diluted EPS $15.50 to $17.50
Amendment No. 5 dated October 27, 2026 adds $70 million of term A-1 loans, returns the term loan A facility to $1.4 billion, and extends the $1.5 billion revolver to October 28, 2031
Paysign reported third-quarter 2026 revenue of $30.80 million, up 42.6%, and GAAP net income of $6.74 million, or $0.11 per diluted share, versus $0.04 a year earlier. The company raised its full-year 2026 net income, diluted EPS and Adjusted EBITDA guidance and confirmed its revenue outlook, but a plasma customer's decision to move processing for 113 centers will reduce fourth-quarter results.
Q3 2026 revenue was $30.80 million, up 42.6%; pharma revenue rose 109.8% to $16.62 million, and plasma revenue rose 7.5% to $13.83 million.
GAAP net income was $6.74 million, or $0.11 per diluted share, versus $2.22 million, or $0.04 per diluted share, in Q3 2025.
Full-year 2026 guidance: net income $23.0 million to $24.0 million, diluted EPS $0.37 to $0.38, Adjusted EBITDA $38.5 million to $40.0 million; revenue outlook of $114.0 million to $117.0 million was confirmed.
A plasma customer will move payment processing for 113 centers to another provider by year-end; the estimated Q4 impact is $1.5 million in revenue and $700 thousand in gross profit.
Zeta Global reported third-quarter 2026 revenue of $493 million, up 46% from a year earlier, and GAAP net income of $38 million after a year-earlier net loss of $3.6 million. The company also raised its full-year 2026 revenue and GAAP EPS guidance, which gives shareholders a higher outlook than before the report.
Q3 2026 revenue was $493 million, up 46% year over year and $22 million above the guidance midpoint
Q3 2026 GAAP net income was $38 million and diluted GAAP EPS was $0.14, versus a net loss of $3.6 million in Q3 2025
Full-year 2026 revenue guidance raised to $1,853 million to $1,857 million, up $37 million at the midpoint from $1,818 million
Full-year 2026 GAAP EPS guidance raised to $0.22 to $0.24, up $0.13 at the midpoint from $0.09 to $0.11
Ultralife reported third-quarter 2026 sales of $48.3 million, up 11.3% from a year earlier, with GAAP net income of $2.4 million, or $0.14 per share, compared with a loss of $0.07 per share in the 2025 quarter. The company had already agreed on October 27, 2026 to be acquired by EnerSys in an all-cash transaction valued at approximately $320 million, which is expected to close in the first quarter of 2027, so Ultralife will not hold a conference call on the results.
Q3 2026 sales of $48.3 million vs. $43.4 million in Q3 2025; gross margin 27.5% vs. 22.2%
Operating income of $3.2 million vs. an operating loss of $1.0 million a year earlier; GAAP EPS $0.14 vs. ($0.07)
Backlog of $136.0 million at quarter end, up from $117.5 million at the end of Q2 2026
All-cash acquisition by EnerSys (NYSE: ENS) valued at approximately $320 million, including assumed net debt; expected close in Q1 2027
Nkarta reported initial clinical data for NKX019, its allogeneic CAR NK cell therapy candidate, in myositis and systemic sclerosis, based on small patient groups with limited follow-up. Among 40 patients treated across five indications, the company reported no deaths and no treatment discontinuations due to adverse events, and it has amended its dosing schedule and plans upcoming FDA discussions on registrational pathways.
Myositis: 5 of 6 patients (83%) at the 4 billion-cell dose with at least three months of follow-up achieved moderate or major Total Improvement Score responses.
Systemic sclerosis: 6 of 7 patients (86%) at the 4 billion-cell dose reached an rCRISS-25 response or greater by Day 90; 5 of 7 (71%) reached rCRISS-50.
Safety: infusion-related reactions occurred in five patients (12.5%), mostly grade 1, and all resolved within 24 to 48 hours.
Nkarta amended protocols to dose on Days 0, 2 and 4, plans to evaluate 6 billion cells per dose, and expects to report additional follow-up in the first half of 2027.
Veradermics reported positive topline 12-month results from Part B of Study '302', a Phase 2/3 trial of its lead candidate VDPHL01 in 519 men with mild-to-moderate pattern hair loss, and reported no new safety signals. The filing covers clinical trial data only and includes no revenue, earnings, or guidance figures, and the drug has not been approved for sale.
Non-vellus hair count rose 43.9 hairs/cm2 (twice daily) and 29.7 hairs/cm2 (once daily) from baseline to Month 12 in the continued group.
At Month 12, 89.1% (twice daily) and 79.8% (once daily) of continued-group participants reported visible improvement in hair coverage on the AAIRS scale.
No treatment-related serious adverse events and no adverse event-related study discontinuations were reported between Month 6 and Month 12.
The company plans to announce data from Study '306' in women in the first half of 2027.
Telos Corporation reported third quarter 2026 revenue of $55.2 million, up from $51.4 million a year earlier, and GAAP net income of $4.4 million, or $0.06 per diluted share, compared with a net loss of $2.1 million a year earlier. The company also raised its full-year 2026 revenue and adjusted EBITDA outlook, which points to stronger results for shareholders.
Q3 2026 revenue was $55.2 million, versus $51.4 million in Q3 2025.
GAAP net income was $4.4 million ($0.06 per diluted share), compared with a net loss of $2.1 million ($0.03 per share) a year earlier.
Full-year 2026 revenue outlook was raised to $198.2 million-$200.7 million from $187 million-$195 million.
Full-year 2026 adjusted EBITDA outlook was raised to $32.3 million-$34.1 million from $23.6 million-$28.6 million.
Vir Biotechnology said its pivotal Phase 3 ECLIPSE 1 trial of elebsiran and tobevibart in adults with chronic hepatitis delta met its primary and key secondary endpoints, with data presented at the AASLD Liver Meeting on November 8, 2026. The company also released expanded Phase 2 SOLSTICE data and preliminary, exploratory findings on treatment discontinuation, which the company itself says are interim and not a complete assessment of safety or efficacy.
ECLIPSE 1 primary endpoint: 44% of patients on elebsiran and tobevibart reached undetectable virus plus ALT normalization at Week 48, versus 0% in the delayed treatment group at Week 12 (p<0.0001)
Key secondary endpoint: 79% reached undetectable virus at Week 48, versus 0% in the delayed treatment group
SOLSTICE Week 96: 100% (28/28) of patients who completed Week 96 of combination therapy reached undetectable viremia
Exploratory analysis: 10 patients discontinued treatment; all 10 achieved SVR12, with 7 reaching SVR24 and 1 reaching SVR48; the filing states these data are preliminary and not a claim of cure
Delcath Systems reported third-quarter 2026 revenue of $35.1 million, up from $20.6 million a year earlier, and net income of $7.0 million, compared with $0.8 million. The company raised its full-year 2026 revenue guidance to $115 million to $117 million, which signals continued growth in HEPZATO KIT sales for shareholders.
Q3 2026 net income of $7.0 million, or $0.17 diluted per share, versus $0.8 million, or $0.02 per share, in Q3 2025
Q3 2026 HEPZATO KIT revenue of $32.7 million, up from $19.3 million; non-GAAP adjusted EBITDA of $11.5 million, up from $5.3 million
2026 guidance raised to $115 million to $117 million in total revenue, with gross margins of 87% to 89% and positive adjusted EBITDA
Cash and investments of $104.3 million as of September 30, 2026, with no debt
RB Global reported third-quarter 2026 results with revenue up 17% year over year to $1.3 billion and net income up 47% to $140.2 million, helped by a one-time $18.2 million excise tax refund. The company raised its full-year 2026 GTV growth outlook to 14% to 15% from 9% to 11% and narrowed its adjusted EBITDA range to $1,525 million to $1,545 million from $1,495 million to $1,545 million, while also declaring a $0.33 quarterly dividend.
Diluted EPS was $0.70, up 63%; diluted adjusted EPS was $1.03, up 11%
Full-year 2026 GTV growth outlook raised to 14% to 15% from 9% to 11%; adjusted EBITDA low end raised to $1,525 million
Repurchased about 3.9 million shares for $350.0 million in the quarter; $500.0 million remained under the NCIB as of September 30, 2026
Quarterly dividend of $0.33 per share payable December 17, 2026, to holders of record November 25, 2026
Air Industries Group reported results for the three and nine months ended September 30, 2026, in a press release furnished under Item 2.02. Third-quarter net sales rose 41.1% and the company swung to net income from a loss a year earlier, though results include merger-related costs tied to its pending merger with Tenax Aerospace Acquisition, LLC.
Q3 2026 net sales were $14.6 million, up from $10.3 million in Q3 2025; net income was $946,000 versus a net loss of $44,000.
Nine-month net sales were $38.2 million, up 8.7%, and the net loss narrowed to $902,000 from $1.5 million.
Q3 operating costs included $539,000 of stock compensation and merger-related expenses, with $503,000 of merger-related expense.
The company cited October 2026 net sales of about $5.6 million and firm customer orders in backlog of $95.4 million.
Faeth Therapeutics reported preliminary topline results from its Phase 2 PIK-201 trial of PIKTOR with paclitaxel in 42 treated patients with advanced endometrial cancer, using an October 30, 2026 efficacy data cut. The confirmed objective response rate was 33% (12 of 36 efficacy-evaluable patients) and preliminary median progression-free survival was 7.4 months, and the company said the data support advancing to a Phase 3 trial. The results are preliminary, the trial is single-arm, and 64% of patients had a grade 3 or higher treatment-related adverse event.
Confirmed ORR of 33% (12 of 36); unconfirmed ORR of 36% (13 of 36); 44% confirmed ORR (7 of 16) in patients with a PIK3CA mutation
Preliminary median PFS of 7.4 months (95% CI 5.3 to NR); 6-month PFS rate of 62%
64% of patients had a grade 3 or higher treatment-related adverse event; 2 patients (5%) discontinued due to treatment-related adverse events; no treatment-related deaths
Company webcast held November 9, 2026 at 8:00 a.m. ET
Select Water Solutions reported third-quarter 2026 revenue of $412 million, up 28% from a year earlier, and net income of $22.9 million, compared with $2.3 million in the third quarter of 2025. The company guided fourth-quarter Adjusted EBITDA to $95 million to $100 million and raised its 2026 net capital expenditure outlook to about $300 million to $310 million, while reporting that it closed the Pilot Water acquisition after quarter end.
Revenue was $412 million, up $90 million or 28% year over year; Adjusted EBITDA was $93.5 million, up from $59.5 million a year earlier.
Fourth-quarter 2026 Adjusted EBITDA is expected to be $95 million to $100 million; 2026 net capital expenditures are now expected to be about $300 million to $310 million.
After quarter end, the company issued $900 million of 7.625% senior notes due November 1, 2034, and entered a new $500 million revolving credit facility that was undrawn as of November 9, 2026.
NRG Energy agreed to sell six natural-gas generation assets, totaling 4.9 GW, to an affiliate of LS Power for $4 billion in cash, subject to customary adjustments. The sale is targeted to close in the second quarter of 2027, pending regulatory approvals. NRG plans to use the proceeds for $3 billion of share repurchases across 2026 and 2027 and $2 billion of debt reduction at closing.
Purchase price of $4 billion in cash, subject to working capital and other closing adjustments; implied 2027 valuation of 8.0x EV/Adj. EBITDA
Six assets totaling 4.9 GW: Ravenswood (NYISO), Ocean State Power and Wallingford (ISO-NE), and Jack County, Johnson County and R.W. Miller (ERCOT)
Targeted closing in the second quarter of 2027, subject to HSR, FERC and New York State Public Service Commission approvals
Planned 2027 capital allocation includes $3 billion of share repurchases across 2026 and 2027, with an incremental $1 billion starting before the end of Q4 2026
Constellation Energy reported third quarter 2026 results, with GAAP net income of $1.84 billion, or $5.19 per share, up from $930 million, or $2.97 per share, a year earlier. The company raised the midpoint of its full-year adjusted operating earnings guidance and narrowed the range to $12.50 to $12.80 per share, which signals stronger expected profit for shareholders.
Q3 2026 adjusted operating earnings were $5.06 per share, compared with $3.04 per share in Q3 2025
Q3 2026 operating revenues were $9.55 billion, compared with $6.57 billion in Q3 2025
Full-year 2026 adjusted operating earnings guidance narrowed to $12.50 to $12.80 per share, with the midpoint raised
Agreed to acquire the Rhode Island State Energy Center from Shell Energy North America for $715 million
NRG reported third-quarter 2026 GAAP net income of $561 million, up from $152 million a year earlier, and Adjusted EBITDA of $2,013 million, up from $1,205 million. The company reaffirmed its 2026 guidance, initiated 2027 guidance, and agreed to sell six gas-fired generation assets totaling 4.9 GW to LS Power for $4 billion in cash, with closing expected in the second quarter of 2027.
Q3 2026 GAAP EPS (basic) was $2.59 versus $0.70 a year earlier; Adjusted EPS was $4.68 versus $2.78.
2026 guidance reaffirmed, including Adjusted EPS of $7.90 to $9.90 and Adjusted EBITDA of $5,325 million to $5,825 million.
2027 guidance initiated, with Adjusted EPS of $8.05 to $10.05; the 2027 plan includes $1 billion of share repurchases and an 8% dividend increase to $2.05 per share.
The 4.9 GW sale to LS Power is for $4 billion in cash, subject to closing adjustments and approvals including HSR, FERC and the NYSPSC.
ImmunityBio said its ANKTIVA plus BCG combination met the primary efficacy endpoint in Cohort A of the randomized QUILT-2.005 trial in BCG-naive non-muscle invasive bladder cancer, with 370 subjects. The company plans to submit a supplemental Biologics License Application to the FDA by year-end 2026, which could expand ANKTIVA's indication to earlier-stage patients.
Trial of 370 subjects compared ANKTIVA plus BCG with BCG alone; the combination showed a statistically significant efficacy improvement in carcinoma in situ patients.
No treatment-related deaths were reported; common adverse events were consistent with BCG alone.
Supplemental BLA is on track for FDA submission by year-end 2026; more study details will be presented at an upcoming medical congress.
Kodiak Gas Services reported third quarter 2026 net income attributable to common shareholders of $71.5 million, or $0.70 per diluted share, compared with a net loss of $14.0 million a year earlier. The company also raised its full-year 2026 adjusted EBITDA and discretionary cash flow guidance, reflecting higher revenue and the DPS acquisition, which closed April 1, 2026.
Total revenues were $401.8 million, up from $322.7 million in the third quarter of 2025.
Net income attributable to common shareholders was $71.5 million, or $0.70 per diluted share, versus a loss of $14.0 million, or $0.17 per share, a year earlier.
Full-year 2026 adjusted EBITDA guidance was raised to $840 million to $860 million; discretionary cash flow guidance rose to $580 million to $600 million.
The quarterly dividend was $0.51 per share, and the share repurchase program was extended to December 31, 2027, with about $31.7 million available.
Edesa Biotech entered a Collaboration and License Agreement dated November 8, 2026, giving Kyorin Pharmaceutical exclusive rights to develop and sell paridiprubart for ARDS in Japan, while Edesa keeps rights elsewhere, including the United States, Europe and Canada. The deal provides a $12 million upfront payment, milestone payments and royalties, and Edesa also gave notice that it is terminating its at-the-market share sales agreement with H.C. Wainwright, effective November 16, 2026.
Kyorin pays a one-time, non-refundable upfront payment of $12 million
Development and regulatory milestones of up to $55 million, plus sales-based milestones of up to ¥12.0 billion
Kyorin pays tiered, low double-digit royalties on net sales in Japan
ATM agreement with H.C. Wainwright terminated effective November 16, 2026, with no termination penalties
DTE Energy said it is selling primarily all of its DTE Vantage business for approximately $3 billion to institutional investors advised by J.P. Morgan Asset Management, with closing targeted in the first half of 2027. The company also raised its long-term operating EPS growth target to greater than 9% through 2031, up from a prior 6% to 8% range, and increased its five-year utility capital plan to $44 billion, which it says is nearly 30% above the prior plan.
Transaction value of approximately $3 billion for primarily all DTE Vantage assets, excluding EES Coke and several named custom energy solutions and renewable energy sites
Target closing in the first half of 2027; sale proceeds will be invested in utility businesses, reducing equity and debt needs
Operating EPS growth target of greater than 9% from 2027 to 2031, versus prior 6% to 8% growth profile; 2026 operating EPS guidance of $7.59 to $7.73 remains, with the company positioned to achieve the high end
Average annual equity issuances targeted at about $1 billion from 2027 to 2031; dividend to increase 7% in 2027
OneMedNet said it expects preliminary third-quarter 2026 revenue of about $1 million, up 242% from the prior quarter and 465% from the year-earlier quarter. It also guided to fourth-quarter 2026 revenue of $12 million to $14 million, pending customer acceptance of delivered data by quarter-end. The third-quarter figures remain preliminary and may change before the Form 10-Q, expected by November 16, 2026.
Preliminary Q3 2026 revenue of about $1 million for the quarter ended September 30, 2026, up 242% from the prior quarter and 465% from Q3 2025.
Q4 2026 revenue guidance of about $12 million to $14 million, pending customer acceptance of delivered data by quarter-end.
Q3 results are preliminary and subject to adjustment; the Form 10-Q is expected by November 16, 2026.
Strive reported GAAP net income of $509.0 million for the quarter ended September 30, 2026, compared with losses in the comparable 2025 periods. The filing attributes the result to a $533.7 million net unrealized gain on digital assets, while total revenues were $2.7 million. Shareholders should note the gain is a fair value adjustment on bitcoin, not operating income.
GAAP net income was $509.0 million, or $5.24 per diluted share, for the three months ended September 30, 2026; non-GAAP adjusted net income attributable to common stockholders was $494.6 million, or $5.46 per diluted share.
Net unrealized gain on digital assets was $533.7 million; total operating expenses were $38.7 million.
Strive acquired 8,136 bitcoin in the third quarter and 15,124 bitcoin from October 1 through October 30, 2026.
On October 20, 2026, Strive completed an offering of 7,000,000 SATS shares for net proceeds of approximately $609.0 million; cash and cash equivalents were $490.4 million as of October 30, 2026.
PPL reported third-quarter 2026 GAAP earnings of $367 million, or $0.49 per share, compared with $318 million, or $0.43 per share, in the third quarter of 2025. The company also narrowed its full-year 2026 ongoing earnings forecast to a range of $1.92 to $1.96 per share and increased its long-term annual EPS growth target to 7% to 9% through at least 2030, supported by a $25 billion capital investment plan.
Announced third-quarter 2026 reported GAAP earnings of $0.49 per share on net income of $367 million.
Achieved third-quarter ongoing EPS of $0.54 compared to $0.48 in 2025.
Increased long-term annual EPS growth target to 7% to 9% through at least 2030.
Announced a $25 billion capital plan for 2027 to 2030, driving average annual rate base growth of 10%.
Sunstone Hotel Investors reported third-quarter 2026 net income attributable to common stockholders of $38.7 million, or $0.21 per diluted share, compared with a net loss of $2.9 million, or $(0.02) per share, a year earlier. The company raised its full-year 2026 guidance, including adjusted FFO per diluted share of $1.00 to $1.03, up from $0.93 to $0.98, and the quarter included a $31.5 million gain on sale of assets. For shareholders, the results and higher outlook reflect stronger hotel demand and continued stock repurchases, which the company says were completed at a discount.
Third-quarter RevPAR rose 11.4% to $235.22; Total RevPAR rose 10.5% to $394.97.
Adjusted FFO per diluted share rose 17.6% to $0.20; Adjusted EBITDAre rose 8.8% to $54.5 million.
2026 guidance raised: net income attributable to common per diluted share now $0.46 to $0.49 (prior $0.37 to $0.42); RevPAR growth now 9.5% to 10.5% (prior 7.0% to 9.0%).
From the start of 2026 through November 5, 2026, the company repurchased $196.9 million of common and preferred stock, with $310.6 million remaining under its authorization.
Enbridge reported third-quarter 2026 GAAP earnings attributable to common shareholders of $1.3 billion, or $0.59 per share, up from $0.7 billion, or $0.30 per share, a year earlier, and adjusted earnings of $1.1 billion, or $0.49 per share, up from $0.46. The company reaffirmed its 2026 guidance and said CEO Greg Ebel will retire in January, with Michele Harradence to lead the company. All figures are in Canadian dollars.
Q3 GAAP earnings attributable to common shareholders of $1.3 billion ($0.59 per share) vs. $0.7 billion ($0.30) in Q3 2025; the increase was primarily due to non-cash, unrealized changes in the value of derivative financial instruments.
Q3 adjusted earnings of $1.1 billion ($0.49 per share) vs. $1.0 billion ($0.46) in Q3 2025; adjusted EBITDA of $4.4 billion vs. $4.3 billion.
2026 guidance reaffirmed: adjusted EBITDA of $20.2 billion to $20.8 billion and DCF per share of $5.70 to $6.10.
Greg Ebel is retiring in January; Michele Harradence will lead Enbridge.
Vistra Corp. reported third quarter 2026 net income of $1,140 million and ongoing operations adjusted EBITDA of $2,378 million, representing more than 50% growth year over year. The company raised and narrowed its full-year 2026 guidance, initiated 2027 guidance ranges, and authorized an additional $1.5 billion for share repurchases. Shareholders also saw the completed acquisition of Cogentrix Energy and the commencement of new solar operations.
GAAP third quarter 2026 Net Income reached $1,140 million, up from $652 million in the third quarter of 2025.
Ongoing Operations Adjusted EBITDA grew over 50% year over year to $2,378 million for the quarter.
Board of Directors authorized an additional $1.5 billion of share repurchases, expected to be used by year-end 2028.
2026 Ongoing Operations Adjusted EBITDA guidance range was narrowed and raised to $7.1 billion to $7.5 billion.
Moderna reported third-quarter 2026 revenue of $1.3 billion and net income of $0.2 billion, returning to a profit compared to a net loss in the same period last year. Driven by this performance and pipeline progress, the company raised its full-year 2026 revenue growth outlook to 15% to 25% and increased its expected year-end cash and investments balance to between $8.1 billion and $8.3 billion. Shareholders also received updates on positive Phase 3 data for intismeran in melanoma and the U.S. FDA approval of the mFLUSIVA vaccine.
Third-quarter 2026 total revenue grew 29% year-over-year to $1.3 billion, with GAAP net income of $162 million or $0.38 per diluted share.
Full-year 2026 expected revenue growth was raised to 15% to 25%, up from the previous expectation of up to 10% growth.
Year-end 2026 cash and investments are now projected to be $8.1 billion to $8.3 billion, bolstered by operational execution and a $2.6 billion net proceeds convertible notes offering.
Research and development expenses for 2026 are now expected to be approximately $2.7 billion, reduced from the prior estimate of approximately $2.9 billion.
Atmus reported third-quarter 2026 net sales of $510 million, up 13.9% from a year earlier, and net income of $61 million, or $0.74 per diluted share, compared with $0.66 a year earlier. The company raised its full-year 2026 outlook and its Board approved a new $300 million share repurchase program that replaces the prior program, which had $28.9 million remaining.
Q3 2026 net sales of $510 million, up from $448 million in Q3 2025, driven mainly by the Koch Filter acquisition
Diluted EPS of $0.74 versus $0.66 a year earlier; adjusted EPS of $0.77 versus $0.69
Full-year 2026 adjusted EPS guidance raised to $2.90 to $3.05; net sales guidance raised to $2,010 million to $2,035 million
New $300 million repurchase program effective immediately; no expiration date and no obligation to buy any amount
Elanco Animal Health Inc reported third quarter 2026 revenue of $1.265 billion, representing an 11% increase year-over-year, and net income of $18 million. Driven by strong demand and gross margin expansion, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted earnings per share.
Third quarter revenue reached $1.265 billion, up 11% reported and 9% organic constant currency.
Reported net income was $18 million, while adjusted EPS was $0.27.
Full year 2026 revenue guidance was raised to $5.155 billion to $5.18 billion.
Net leverage ratio improved to 2.9x Adjusted EBITDA at the end of the third quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.